GlycoMimetics (GLYC) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. SPY
2. CRWV
3. SLGN
4. EYPT
5. SLN
6. PNB:IN
7. LTM:IN
8. CHRD
9. IRON
10. MANE

Go back to GlycoMimetics (GLYC) Tops Q2 EPS by 4c

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022

August 3, 2022 7:00 AM EDT

U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) application to study GMI-1687 in Sickle Cell Disease (SCD) received in June The Company previously disclosed and will continue to update its projection of mid-year 2023 for the survival events trigger for its pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Progress in data collection now enables the Company to share a comparison of the demographics of the pivotal Phase 3 study to those of the completed Phase 2 study Conference call and webcast today... More